News for 10x Genomics, Inc. (TXG)

June 3 - Cathie Wood's Ark Invest sold 1,594 shares of Tesla Inc (TSLA) through its ARK Innovation ETF (ARKK), offloading a position worth $546,247, according t

On Monday, Cathie Wood-led Ark Invest sold shares of Tesla and Palantir, amidst competition and data misuse concerns. Ark also made significant trades in other companies, such as eToro and Illumina.

Cathie Wood underscored the application of AI in the healthcare sector by sharing new research by Mass General Brigham.

Morgan Stanley has updated its price target for 10x Genomics (TXG), adjusting it downwards from $26.00 USD to $18.00 USD. This change reflects a 30.77% decrease

[url="]Bruker Corporation[/url](Nasdaq: BRKR) today announcedthat Bruker and 10x Genomics have reached a final settlement to resolve their patent disputes and

On May 13, 2025, UBS analyst Dan Leonard announced an update on 10x Genomics (TXG), maintaining a 'Neutral' rating but lowering the price target. The updated pr

In recent analyst activity, Goldman Sachs has adjusted its price target for 10x Genomics (TXG). The financial firm has maintained its "Sell" rating on the stock

On May 12, 2025, Canaccord Genuity, under the guidance of analyst Kyle Mikson, announced an adjustment to their price target for 10x Genomics (TXG). The firm ma

Canaccord has revised its price target for 10x Genomics (TXG), dropping it from $18 to $15 while maintaining a Buy rating for the stock. This adjustment stems f

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.

Stifel has revised its price target for 10x Genomics (TXG), reducing it from $18 to $15, yet maintaining a Buy rating on the stock. This adjustment follows the

TD Cowen analyst Dan Brennan has adjusted the price target for 10x Genomics (TXG), decreasing it to $11 from a previous target of $15 while maintaining a Hold r

JPMorgan has revised its price target for 10x Genomics (TXG), lowering it from $12 to $9, while maintaining a Neutral rating after the company's first-quarter r

Total Revenue: $154.9 million for Q1 2025.Adjusted Revenue: $138.1 million, down 2% year-over-year, excluding license and royalty revenue.Consumables Revenue:

10x Genomics Inc. criticized U.S. government budget cuts for academic research, withdrew full-year guidance, and shifted to quarterly forecasts.

May 08, 2025 / 08:30PM GMTOperator Ladies and gentlemen, thank you so much for standing by, and welcome to 10x Genomics first quarter 2025 earnings conference c

10x Genomics (TXG) Q1 earnings announcement on May 8th with EPS estimate at -$0.29 and revenue at $132.51M. Discover key trends and analyst expectations.

ARK ETFs sold 376,874 Palantir (PLTR) shares for $46.65 million, continuing a week-long reduction, while investing $10.45 million in 237,374 Guardant Health (GH) shares, signaling a shift from data analytics to precision oncology. Significant purchases included $10.17 million for 283,186 Twist Bioscience (TWST) shares and $8.75 million for 55,623 Natera…

Cathie Wood's Ark Invest Makes Bold $9.8M Robinhood Bet While Dumping Palantir Ahead of Earnings.